New algorithm predicts rheumatoid arthritis
Based on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1306 entries already.
Entries by Thomas Gabrielczyk
SARS-CoV2 antibody tests: not suited for individual diagnosis?
/in News/by Thomas GabrielczykAn international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Vaccine to protect from any viral infection
/in News/by Thomas GabrielczykTwo companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
Abivax bags 36m fund for COVID-19 programme
/in News/by Thomas GabrielczykFrench Abivax SA has received a 36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.
4Teen4s DPP3 predicts burn mortality
/in News/by Thomas Gabrielczyk4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.
S-Protein: Glycosylation pattern revealed
/in News/by Thomas GabrielczykBritish researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.
Newron terminates sarizotan development in Rett syndrome
/in News/by Thomas GabrielczykNewron Pharmaceuticals S.p.A.s Sarizotan failed to meet efficacy endpoints in the Phase III STARS study.
Bone Therapeutics bags 11m
/in News/by Thomas GabrielczykBelgian Bone Therapeutics SA has secured 11m to foster development of its late stage pipeline candidates.
Cevec launches ELEVECTA platform
/in News/by Thomas GabrielczykCevec Pharmaceuticals GmbH has launched a new, scalable production platform for AAV gene therapy vectors.
Artes enters COVID-19 vaccine race
/in News/by Thomas GabrielczykGerman vaccine developer ARTES Biotechnology GmbH will develop a COVID-19 subunit vaccine based on virus-like particles (VLP), which include two proteins of SARS-CoV-2.